Clinical Trials
7 trialsNCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02506959 2025-03-18
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05350163 2024-12-10
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Baptist Health South Florida
Phase 1 Terminated
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT00569868 2011-08-12
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
University of Arkansas
Phase NA Completed